'Patent term' diaporamas de présentation

OPTEON

Topic 10 Fundamentals of Licensing Agreements WIPO-KIPO-KIPA IP Panorama Business School Investment Summit 7 October 2008 Geneva. OPTEON. Philip Mendes. Level 3, 33 Queen St Brisbane QLD, Australia Ph + 61 7 3211 9033 Fax + 61 7 3211 9025 philip@opteon.com.au. Outline.

1.29k views • 103 slides

1.15k views • 98 slides

Patent Term Adjustments and Extensions

Patent Term Adjustments and Extensions. Karin L. Ferriter Patent Attorney Office of Intellectual Property Policy and Enforcement USPTO (571) 272-9300 karin.ferriter@uspto.gov November 6, 2007. TRIPs Article 33 - Term of Protection.

1.66k views • 56 slides

Patents in the pharmaceutical industry

Patents in the pharmaceutical industry. Lars Sparre Conrad Senior Patent Counsel Corporate Patents and Trademarks. The patent department. Chemical engineer, DTU (chemistry), 1990 PhD, DTU (bio-inorganic chemistry), 1992 European Patent Attorney, 2005

1.04k views • 54 slides

PETITIONS PRACTICE COMMON ERRORS

PETITIONS PRACTICE COMMON ERRORS. Office of Patent Legal Administration. 37 CFR 1.57 Incorporation by reference. Filing a petition when a filing date has been granted. Merely an amendment is needed.

1.18k views • 44 slides

Patent Term Extension to drugs and new regenerative medical products in Japan

Patent Term Extension to drugs and new regenerative medical products in Japan. February 2015, INDIA Kiyoshi Kuzuwa Patent Attorney. Table of contents. Patent Term Extension (max. 5 yrs.) for pharmaceutical/agrochemical products

414 views • 41 slides

Robert M. Hansen The Marbury Law Group PLLC AIPLA

555 views • 40 slides

Market Exclusivity Paradigm

Market Exclusivity Paradigm. Gregory J. Glover, MD, JD Pharmaceutical Law Group Gregory.Glover@pharmalawgrp.com www.pharmalawgrp.com. Market Exclusivity Paradigm Overview.

537 views • 40 slides

Patent Term extension in the Japan Patent system

10 th International Seminar of MarkPatent.ORG on IP Rights February.14-15, Ahmedabad INDIA. Patent Term extension in the Japan Patent system. Kazuaki TASAKA The Tokyo-Marunouchi Law Offices/ Nagasawa Patent Firm. Global Trend of Patent Term Extension Patent Term Extension of Japan

371 views • 34 slides

Patent Term Matters

412 views • 32 slides

Wang, Mei-hua Director General Intellectual Property Office MOEA, Taiwan June 2011

Pharmaceutical Issues in Patent Act Amendment in Taiwan. Wang, Mei-hua Director General Intellectual Property Office MOEA, Taiwan June 2011. Outline. Number of Patent Applications for Medical Industry(2008~2010).

360 views • 23 slides

TRIPS-Plus Provisions in EU FTAs Impact on Public Health and Access to Medicines

TRIPS-Plus Provisions in EU FTAs Impact on Public Health and Access to Medicines. Mohammed El Said (UCLAN) IP and Access to Medicines UNDP, Kiev 22-23 June 2010. Overview. EU and IP protection EU and bilateral trade agreements Some TRIPS-Plus provisions under EU bilateral trade agreements.

459 views • 23 slides

FDA Regulatory Exclusivity and Patent Protection for Drugs

FDA Regulatory Exclusivity and Patent Protection for Drugs. American Intellectual Property Law Assn. IP Practice in Japan Committee October 25-36, 2005 Darryl Webster Wyeth. FDA Regulatory Exclusivity and Patent Protection for Drugs.

400 views • 19 slides

THE FUTURE OF THE PATENT SYSTEM IN EUROPE: NOSTALGIA IS NOT A GOOD ADVISER EPIP Conference, Lund

THE FUTURE OF THE PATENT SYSTEM IN EUROPE: NOSTALGIA IS NOT A GOOD ADVISER EPIP Conference, Lund. Alison Brimelow President of the EPO. September, 2007, Lund. Italian Presidency / European Commission Conference 2003 "IP Quo Vadis?". "Business as usual" "If only they understood"

258 views • 18 slides

WTO Side Event Hotel Azul Sensatori Carretera Cancun-Puerto Morelos Km. 27.5 Bahia Petempich, Quintana Roo 8 December

WTO Side Event Hotel Azul Sensatori Carretera Cancun-Puerto Morelos Km. 27.5 Bahia Petempich, Quintana Roo 8 December 2010 from 14:00 to 18:30. IP and Climate Change Situating the WTO TRIPS Agreement in policy debate on climate change Jayashree Watal. Disclaimer.

285 views • 14 slides

Momenta Pharmaceuticals, Inc.

408 views • 14 slides

AIPLA

294 views • 12 slides

Interference-in-fact

295 views • 4 slides